Developer docs
API playgroundTry for free, no card

Search company profiles

Biosfer Teslab

Full company profile

uuid002l74n

Namestring
Biosfer Teslab
Legal namestring
BIOSFER TESLAB, SL
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Biosfer Teslab is a privately-held Spanish medical software company, founded in December 2013 as a spin-off of the Universitat Rovira i Virgili (URV) and the Institut d'Investigació Sanitària Pere Virgili (IISPV), headquartered in Reus, Tarragona. The company develops proprietary in vitro diagnostic software and analytical services based on 1H-NMR (proton Nuclear Magnetic Resonance) spectroscopy, applying machine learning and artificial intelligence to derive lipoprotein profiles, glycoprotein signatures (GlycA/GlycB), lipidomic families, and low molecular weight metabolite data from blood and biological samples.

The company's commercial portfolio is anchored by two core products: the Liposcale Test, an advanced lipoprotein profiling test launched in 2020 for cardiovascular risk stratification in clinical settings, and the MetBalance Test, a direct-to-consumer metabolic health assessment launched in 2022 that translates NMR metabolomic data into personalized health visualizations. Complementary revenue comes from fee-for-service Metabolomic Services (lipoprotein profiling, glycoprotein analysis, aqueous metabolome, lipidomic families) provided to universities, research centers, and pharmaceutical companies globally, plus Data Science Services that interpret complex biological data using ML/AI for institutional clients.

Biosfer Teslab operates a sales-led go-to-market with direct B2B engagement of clinicians, cardiologists, lipidologists, and clinical laboratories in Spain, supported by ICEX Next for international expansion, plus direct-to-consumer e-commerce for the MetBalance Test. The company has analyzed over 30,000 samples and produced 100+ peer-reviewed scientific publications. R&D is substantially grant-funded through Spanish public institutions (CDTI, AGAUR, ENISA, ACCIÓ, Ministerio de Ciencia) and European programs (Horizon 2020, Horizon Europe, COST, NextGenerationEU), with a team size of 11–50 employees. Certifications include ISO 13485:2016, ISO 9001:2015, GDPR compliance, AEMPS software development license, and certified innovative SME status.

Short descriptiontext

Biosfer Teslab is a Spanish medical software spin-off that develops NMR-based metabolomics diagnostic tests, including the Liposcale lipoprotein test for cardiovascular risk and the MetBalance consumer metabolic health test, serving clinicians, researchers, and pharma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersReus, Spain
HQ citystring
Reus
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NMR metabolomics, lipoprotein profiling, cardiovascular diagnostics, clinical metabolomics services, in vitro diagnostics
Industry3 codes
PRIMARYHLAGANAG
Metabolomics & Lipidomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • Services-Testing Laboratories8734
  • Services-Medical Laboratories8071
Product category
Clinical Diagnostics Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Liposcale Test Services
TypeProfessional Services
Description

Provides advanced cardiovascular risk stratification lipoprotein testing services to health professionals and clinical laboratories on a fee-per-test basis, including direct-to-professional clinical testing.

biosferteslab.com
2Metabolomic Research Services
TypeProfessional Services
Description

Offers metabolomic analysis services to universities, research centers, and pharmaceutical companies on a project or fee-per-sample basis, supporting biomarker discovery and clinical research.

biosferteslab.com
3MetBalance Test (Direct-to-Consumer)
TypeSubscription Recurring
Description

Consumer-facing metabolic health assessment product available through metbalancetest.com, translating NMR metabolomic data into personalized health insights.

biosferteslab.com
4Data Science Services
TypeProfessional Services
Description

Provides specialized data analysis and interpretation of complex biological data to support research and clinical decision-making for institutional clients.

biosferteslab.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 2 records shown
1Liposcale
Description

Advanced lipoprotein test for cardiovascular risk stratification using NMR spectroscopy, providing comprehensive characterization of lipoprotein profile including lipid content, particle number, and size.

biosferteslab.com
+1 more record
Core offering1 text field

Biosfer Teslab develops and provides medical software and IT tools based on Nuclear Magnetic Resonance (NMR) spectroscopy for the analysis of fluids and biological tissues. The company sells the Liposcale Test for advanced cardiovascular risk stratification through lipoprotein profiling, the MetBalance Test for personalized consumer metabolic health monitoring, NMR-based metabolomic research services, and data science services for biological data interpretation, all powered by proprietary computational methods and AI/ML.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Detection of increased atherogenic small TG-rich remnant lipoproteins and small LDL particles that are not identifiable through standard lipid measures
+3 more records
Product overview1 text field

Biosfer Teslab operates as a spin-off of the University Rovira i Virgili and Institut d'Investigació Sanitària Pere Virgili, providing NMR-based diagnostic services and products. The portfolio centers on the Liposcale Test for advanced cardiovascular risk assessment through lipoprotein analysis, complemented by the MetBalance Test for personalized metabolic health monitoring. The company offers Metabolomic Services for research applications and Data Science Services for biological data interpretation. All products leverage Nuclear Magnetic Resonance (NMR) spectroscopy technology combined with AI and machine learning for precision medicine applications.

Product and service4 records
1Liposcale Test
CategoryCardiovascular diagnostic test
Description

Advanced lipoprotein testing using 1H-NMR spectroscopy that provides comprehensive characterization of lipoprotein profiles including particle number, size, and lipid content for cardiovascular risk stratification. Identifies atherogenic small TG-rich remnant lipoproteins, small LDL particles, remnant cholesterol, and TG enrichment in HDL. Targeted at health professionals including cardiologists, endocrinologists, lipid specialists, and general practitioners for patient cardiovascular risk assessment and dyslipidemia management.

2MetBalance Test
CategoryConsumer metabolic health assessment
Description

Comprehensive metabolic health assessment tool that translates NMR-based blood analysis, artificial intelligence, and data visualization into personalized metabolic state evaluation, generating metabolic age images and health status visualizations. Targeted at health-conscious individual consumers for personal metabolic health monitoring, wellness optimization, and metabolic age tracking via metbalancetest.com.

3Metabolomic Services
CategoryResearch analytical services
Description

Research analytical services providing NMR-based metabolomics analysis including advanced lipoprotein profiling, glycoprotein characterization (GlycA and GlycB), aqueous plasma metabolome (LMWM), and lipid family analysis for biomedical and clinical research. Targeted at academic research groups at universities, research centers, and pharmaceutical/biotech companies for biomarker discovery, clinical studies, epidemiological investigations, and multi-omic integration projects.

4Data Science Services
CategoryData analytics services
Description

Analytical and interpretive services for complex biological data supporting research and clinical decision-making through advanced computational analysis and machine learning approaches. Targeted at institutional clients including research institutions and pharmaceutical companies needing support for biomarker discovery and clinical research data interpretation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1AM BIOTA
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

Biosfer Teslab and AM BIOTA announced a unique collaboration to develop a personalized medicine test combining metabolomics and microbiota analysis for improved patient stratification and health management.

biosferteslab.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-09-01
Description

Laboratorios Rubió, a family company specializing in therapeutic solutions for low-prevalence diseases, co-developed a pioneering cardiovascular prediction test in Europe with Biosfer Teslab, planned for launch across the European market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-12-01
Description

Biosfer Teslab is a spin-off company of the Rovira i Virgili University (URV), originating from the university's research environment. The company maintains close ties with URV's research groups and benefits from academic collaboration, talent pipeline, and research infrastructure.

4Institut d'Investigació Sanitària Pere Virgili (IISPV)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-12-01
Description

Biosfer Teslab is a spin-off of the Institut d'Investigació Sanitària Pere Virgili (IISPV), collaborating closely with IISPV's metabolomics platform led by Dr. Xavier Correig. The company co-participates in research projects including the VISIONING COVID-19 project as CO-IP with Dr. Correig.

biosferteslab.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

International testing laboratory group operating across clinical diagnostics, pharma services, and metabolomics-adjacent analytical services. Broad incumbent with overlapping metabolomics, biomarker, and clinical testing capabilities relevant to Biosfer's research services business.

TypeEmerging player
Description

Swedish proteomics company providing high-multiplex biomarker discovery and clinical validation services to pharma and academic researchers. Comparable as a European specialty omics platform serving the same pharma biomarker discovery and clinical research customer segments targeted by Biosfer's research services.

TypeDirect peer
Description

US-based metabolomics services provider offering untargeted metabolomics profiling and lipidomics for pharma, academic, and consumer health clients. Directly competes with Biosfer Teslab's Metabolomic Research Services in biomarker discovery and pharma research support.

TypeDirect peer
Description

Finnish company providing NMR-based metabolomic profiling and cardiovascular risk biomarkers at scale. Directly comparable as the leading commercial NMR metabolomics platform targeting clinical cardiovascular risk and research applications, with analogous biomarker products (e.g., Nightingale's circulating metabolic biomarkers vs. Biosfer's Liposcale).

TypeRegional player
Description

European medical diagnostics services provider with strong presence across continental Europe. Comparable as a regional clinical diagnostics services network that could distribute or adopt NMR-based cardiovascular tests like Liposcale within its pan-European laboratory footprint.

TypeBroad incumbent
Description

Manufacturer of NMR spectrometers and mass spectrometry instruments used in metabolomics research and clinical labs. Relevant as both a potential instrument supplier and an adjacent player expanding into clinical NMR applications, including partnerships with diagnostic developers.

TypeBroad incumbent
Description

Global clinical diagnostics leader that acquired LipoScience (pioneer of NMR lipoprotein analysis). Represents the broad incumbent that has already consolidated the NMR lipoprotein subcategory, posing both a competitive threat and a potential partner/acquirer for Biosfer's Liposcale technology.

TypeBroad incumbent
Description

Largest US clinical laboratory network offering advanced cardiovascular and metabolic testing. Represents the broad incumbent benchmark for advanced lipid and metabolic risk testing commercial scale, against which Biosfer's Liposcale must differentiate to gain clinical adoption.

TypeDirect peer
Description

Norwegian specialized metabolomics laboratory offering NMR- and LC-MS-based biomarker analyses for epidemiological and clinical research. Closely comparable niche metabolomics services provider serving research institutions and pharma, similar in scale and academic origin to Biosfer Teslab.

TypeEmerging player
Description

Specialty diagnostics company developing blood-based biomarker tests for neurodegenerative disease using mass spectrometry and proteomics. Comparable as a focused clinical diagnostics innovator translating advanced analytical technologies into clinical biomarker products, though in a different disease area.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biosfer Teslab

Clinical Diagnostics Softwarebiosferteslab.com

Biosfer Teslab is a Spanish medical software spin-off that develops NMR-based metabolomics diagnostic tests, including the Liposcale lipoprotein test for cardiovascular risk and the MetBalance consumer metabolic health test, serving clinicians, researchers, and pharma.

What Biosfer Teslab does

Biosfer Teslab is a privately-held Spanish medical software company, founded in December 2013 as a spin-off of the Universitat Rovira i Virgili (URV) and the Institut d'Investigació Sanitària Pere Virgili (IISPV), headquartered in Reus, Tarragona. The company develops proprietary in vitro diagnostic software and analytical services based on 1H-NMR (proton Nuclear Magnetic Resonance) spectroscopy, applying machine learning and artificial intelligence to derive lipoprotein profiles, glycoprotein signatures (GlycA/GlycB), lipidomic families, and low molecular weight metabolite data from blood and biological samples.

The company's commercial portfolio is anchored by two core products: the Liposcale Test, an advanced lipoprotein profiling test launched in 2020 for cardiovascular risk stratification in clinical settings, and the MetBalance Test, a direct-to-consumer metabolic health assessment launched in 2022 that translates NMR metabolomic data into personalized health visualizations. Complementary revenue comes from fee-for-service Metabolomic Services (lipoprotein profiling, glycoprotein analysis, aqueous metabolome, lipidomic families) provided to universities, research centers, and pharmaceutical companies globally, plus Data Science Services that interpret complex biological data using ML/AI for institutional clients.

Biosfer Teslab operates a sales-led go-to-market with direct B2B engagement of clinicians, cardiologists, lipidologists, and clinical laboratories in Spain, supported by ICEX Next for international expansion, plus direct-to-consumer e-commerce for the MetBalance Test. The company has analyzed over 30,000 samples and produced 100+ peer-reviewed scientific publications. R&D is substantially grant-funded through Spanish public institutions (CDTI, AGAUR, ENISA, ACCIÓ, Ministerio de Ciencia) and European programs (Horizon 2020, Horizon Europe, COST, NextGenerationEU), with a team size of 11–50 employees. Certifications include ISO 13485:2016, ISO 9001:2015, GDPR compliance, AEMPS software development license, and certified innovative SME status.

Biosfer Teslab firmographics

Firmographics
Name
Biosfer Teslab
Legal name
BIOSFER TESLAB, SL
Website
https://biosferteslab.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Biosfer Teslab is a Spanish medical software spin-off that develops NMR-based metabolomics diagnostic tests, including the Liposcale lipoprotein test for cardiovascular risk and the MetBalance consumer metabolic health test, serving clinicians, researchers, and pharma.
Ownership category
akta.pro rank

Biosfer Teslab industry classification

Industry
Product category
Clinical Diagnostics Software
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGANAG
Metabolomics & Lipidomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGADAK
Material Characterization & Spectroscopy (NMR/FTIR/MS)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • NMR metabolomics
  • Lipoprotein profiling
  • Cardiovascular diagnostics
  • Clinical metabolomics services
  • In vitro diagnostics

Where Biosfer Teslab is headquartered

Location

Headquarters

HQ city
Reus
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Biosfer Teslab business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Liposcale Test Services: Provides advanced cardiovascular risk stratification lipoprotein testing services to health professionals and clinical laboratories on a fee-per-test basis, including direct-to-professional clinical testing.
  2. Metabolomic Research Services: Offers metabolomic analysis services to universities, research centers, and pharmaceutical companies on a project or fee-per-sample basis, supporting biomarker discovery and clinical research.
  3. MetBalance Test (Direct-to-Consumer): Consumer-facing metabolic health assessment product available through metbalancetest.com, translating NMR metabolomic data into personalized health insights.
  4. Data Science Services: Provides specialized data analysis and interpretation of complex biological data to support research and clinical decision-making for institutional clients.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Biosfer Teslab product offering

Product offering

Core offering

Biosfer Teslab develops and provides medical software and IT tools based on Nuclear Magnetic Resonance (NMR) spectroscopy for the analysis of fluids and biological tissues. The company sells the Liposcale Test for advanced cardiovascular risk stratification through lipoprotein profiling, the MetBalance Test for personalized consumer metabolic health monitoring, NMR-based metabolomic research services, and data science services for biological data interpretation, all powered by proprietary computational methods and AI/ML.

Product overview

Biosfer Teslab operates as a spin-off of the University Rovira i Virgili and Institut d'Investigació Sanitària Pere Virgili, providing NMR-based diagnostic services and products. The portfolio centers on the Liposcale Test for advanced cardiovascular risk assessment through lipoprotein analysis, complemented by the MetBalance Test for personalized metabolic health monitoring. The company offers Metabolomic Services for research applications and Data Science Services for biological data interpretation. All products leverage Nuclear Magnetic Resonance (NMR) spectroscopy technology combined with AI and machine learning for precision medicine applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Liposcale: Advanced lipoprotein test for cardiovascular risk stratification using NMR spectroscopy, providing comprehensive characterization of lipoprotein profile including lipid content, particle number, and size.
  • MetBalance Test

Products and services

  • Liposcale Test Advanced lipoprotein testing using 1H-NMR spectroscopy that provides comprehensive characterization of lipoprotein profiles including particle number, size, and lipid content for cardiovascular risk stratification. Identifies atherogenic small TG-rich remnant lipoproteins, small LDL particles, remnant cholesterol, and TG enrichment in HDL. Targeted at health professionals including cardiologists, endocrinologists, lipid specialists, and general practitioners for patient cardiovascular risk assessment and dyslipidemia management.
  • MetBalance Test Comprehensive metabolic health assessment tool that translates NMR-based blood analysis, artificial intelligence, and data visualization into personalized metabolic state evaluation, generating metabolic age images and health status visualizations. Targeted at health-conscious individual consumers for personal metabolic health monitoring, wellness optimization, and metabolic age tracking via metbalancetest.com.
  • Metabolomic Services Research analytical services providing NMR-based metabolomics analysis including advanced lipoprotein profiling, glycoprotein characterization (GlycA and GlycB), aqueous plasma metabolome (LMWM), and lipid family analysis for biomedical and clinical research. Targeted at academic research groups at universities, research centers, and pharmaceutical/biotech companies for biomarker discovery, clinical studies, epidemiological investigations, and multi-omic integration projects.
  • Data Science Services Analytical and interpretive services for complex biological data supporting research and clinical decision-making through advanced computational analysis and machine learning approaches. Targeted at institutional clients including research institutions and pharmaceutical companies needing support for biomarker discovery and clinical research data interpretation.

Quantifiable outcome

  • Detection of increased atherogenic small TG-rich remnant lipoproteins and small LDL particles that are not identifiable through standard lipid measures
  • +3 more outcomes

Companies that use Biosfer Teslab

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Biosfer Teslab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Biosfer Teslab partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • AM BIOTAcoreStrategic or Co-development Partner · 1 April 2024Biosfer Teslab and AM BIOTA announced a unique collaboration to develop a personalized medicine test combining metabolomics and microbiota analysis for improved patient stratification and health management.
  • Laboratorios RubiócoreStrategic or Co-development Partner · 1 September 2014Laboratorios Rubió, a family company specializing in therapeutic solutions for low-prevalence diseases, co-developed a pioneering cardiovascular prediction test in Europe with Biosfer Teslab, planned for launch across the European market.
  • Universitat Rovira i Virgili (URV)coreStrategic or Co-development Partner · 1 December 2013Biosfer Teslab is a spin-off company of the Rovira i Virgili University (URV), originating from the university's research environment. The company maintains close ties with URV's research groups and benefits from academic collaboration, talent pipeline, and research infrastructure.
  • Institut d'Investigació Sanitària Pere Virgili (IISPV)coreStrategic or Co-development Partner · 1 December 2013Biosfer Teslab is a spin-off of the Institut d'Investigació Sanitària Pere Virgili (IISPV), collaborating closely with IISPV's metabolomics platform led by Dr. Xavier Correig. The company co-participates in research projects including the VISIONING COVID-19 project as CO-IP with Dr. Correig.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Biosfer Teslab competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Scientific: International testing laboratory group operating across clinical diagnostics, pharma services, and metabolomics-adjacent analytical services. Broad incumbent with overlapping metabolomics, biomarker, and clinical testing capabilities relevant to Biosfer's research services business.
  • Bruker Corporation: Manufacturer of NMR spectrometers and mass spectrometry instruments used in metabolomics research and clinical labs. Relevant as both a potential instrument supplier and an adjacent player expanding into clinical NMR applications, including partnerships with diagnostic developers.
  • Labcorp: Global clinical diagnostics leader that acquired LipoScience (pioneer of NMR lipoprotein analysis). Represents the broad incumbent that has already consolidated the NMR lipoprotein subcategory, posing both a competitive threat and a potential partner/acquirer for Biosfer's Liposcale technology.
  • Quest Diagnostics: Largest US clinical laboratory network offering advanced cardiovascular and metabolic testing. Represents the broad incumbent benchmark for advanced lipid and metabolic risk testing commercial scale, against which Biosfer's Liposcale must differentiate to gain clinical adoption.

Emerging players

  • Olink Holding: Swedish proteomics company providing high-multiplex biomarker discovery and clinical validation services to pharma and academic researchers. Comparable as a European specialty omics platform serving the same pharma biomarker discovery and clinical research customer segments targeted by Biosfer's research services.
  • C2N Diagnostics: Specialty diagnostics company developing blood-based biomarker tests for neurodegenerative disease using mass spectrometry and proteomics. Comparable as a focused clinical diagnostics innovator translating advanced analytical technologies into clinical biomarker products, though in a different disease area.

Direct peers

  • Metabolon: US-based metabolomics services provider offering untargeted metabolomics profiling and lipidomics for pharma, academic, and consumer health clients. Directly competes with Biosfer Teslab's Metabolomic Research Services in biomarker discovery and pharma research support.
  • Nightingale Health: Finnish company providing NMR-based metabolomic profiling and cardiovascular risk biomarkers at scale. Directly comparable as the leading commercial NMR metabolomics platform targeting clinical cardiovascular risk and research applications, with analogous biomarker products (e.g., Nightingale's circulating metabolic biomarkers vs. Biosfer's Liposcale).
  • Bevital: Norwegian specialized metabolomics laboratory offering NMR- and LC-MS-based biomarker analyses for epidemiological and clinical research. Closely comparable niche metabolomics services provider serving research institutions and pharma, similar in scale and academic origin to Biosfer Teslab.

Regional players

  • Synlab: European medical diagnostics services provider with strong presence across continental Europe. Comparable as a regional clinical diagnostics services network that could distribute or adopt NMR-based cardiovascular tests like Liposcale within its pan-European laboratory footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Biosfer Teslab social profiles

Digital presence

Biosfer Teslab compliance and trust

Trust signal

Compliance5 records

Biosfer Teslab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biosfer Teslab leadership team

Management profile

Number of profiles

Profiles9 records

Biosfer Teslab funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biosfer Teslab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biosfer Teslab

What does Biosfer Teslab do?

Biosfer Teslab develops and provides medical software and IT tools based on Nuclear Magnetic Resonance (NMR) spectroscopy for the analysis of fluids and biological tissues. The company sells the Liposcale Test for advanced cardiovascular risk stratification through lipoprotein profiling, the MetBalance Test for personalized consumer metabolic health monitoring, NMR-based metabolomic research services, and data science services for biological data interpretation, all powered by proprietary computational methods and AI/ML.

Is Biosfer Teslab a public or private company?

Biosfer Teslab is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Biosfer Teslab founded?

Biosfer Teslab was founded in 2013. It employs 11 to 50 people.

Where is Biosfer Teslab based?

Biosfer Teslab is headquartered in Reus, Spain, in the Europe region.

How does Biosfer Teslab make money?

Four revenue lines are on record. Liposcale Test Services are the primary driver. The others are metabolomic Research Services, metBalance Test (Direct-to-Consumer) and data Science Services.

Who are Biosfer Teslab's main competitors?

Broad incumbents on record are Eurofins Scientific, Bruker Corporation, Labcorp and Quest Diagnostics. Emerging players are Olink Holding and C2N Diagnostics. Direct peers are Metabolon, Nightingale Health and Bevital. Synlab is listed as a regional player.

Does Biosfer Teslab have an API?

No public API is recorded for Biosfer Teslab.

What industry is Biosfer Teslab in?

Biosfer Teslab's product category is Clinical Diagnostics Software. Its primary akta.pro industry code is HLAGANAG, Metabolomics & Lipidomics Services, with a secondary code of HLAGADAK, Material Characterization & Spectroscopy (NMR/FTIR/MS). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales